HC Wainwright Boosts Sanara MedTech (NASDAQ:SMTI) Price Target to $51.00

Sanara MedTech (NASDAQ:SMTI) had its target price upped by HC Wainwright from $50.00 to $51.00 in a report released on Wednesday, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Sanara MedTech’s Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.12) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $44.00 price target on shares of Sanara MedTech in a research report on Wednesday, January 22nd.

Sanara MedTech Trading Down 3.3 %

Shares of NASDAQ:SMTI opened at $30.19 on Wednesday. Sanara MedTech has a 12-month low of $26.00 and a 12-month high of $39.08. The company has a market cap of $263.89 million, a PE ratio of -30.49 and a beta of 1.37. The stock has a 50 day moving average of $34.26 and a 200 day moving average of $33.74. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $26.31 million for the quarter, compared to the consensus estimate of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. As a group, equities research analysts expect that Sanara MedTech will post -1.1 EPS for the current year.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently bought and sold shares of SMTI. State Street Corp raised its stake in Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after buying an additional 4,932 shares during the last quarter. Barclays PLC boosted its stake in Sanara MedTech by 323.0% in the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after purchasing an additional 4,376 shares in the last quarter. Geode Capital Management LLC grew its position in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after purchasing an additional 3,755 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Sanara MedTech by 127.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after purchasing an additional 2,272 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of Sanara MedTech during the fourth quarter worth $898,000. 8.10% of the stock is owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.